Try our beta test site
155 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND PCI-32765 [TREATMENT]
Show Display Options
Rank Status Study
1 Active, not recruiting An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Other: Arm A - Post-Chlorambucil Therapy Follow-up;   Drug: Arm B - PCI-32765;   Drug: Second-line PCI-32765;   Drug: Alternative Anticancer Treatment
2 Completed A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
3 Completed Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Conditions: B-Cell Lymphoma;   B-Cell Leukemia
Intervention: Drug: PCI-32765
4 Completed
Has Results
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
5 Completed
Has Results
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: Ibrutinib
6 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
7 Completed
Has Results
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Chlorambucil
8 Active, not recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
9 Active, not recruiting An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
10 Completed
Has Results
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765
11 Active, not recruiting Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
12 Completed Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
13 Recruiting Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Ibrutinib and immunochemotherapies
14 Recruiting Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
15 Recruiting Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab
16 Completed
Has Results
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell B-lymphoma
Intervention: Drug: ibrutinib
17 Completed
Has Results
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
18 Active, not recruiting
Has Results
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: ofatumumab;   Drug: ibrutinib
19 Active, not recruiting Ublituximab + Ibrutinib in Select B-cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Ublituximab;   Drug: Ibrutinib
20 Recruiting Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: bortezomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.